Abstract
Ischemic stroke is a major cause of morbidity and mortality. Whereas dyslipidemia is a major risk factor for coronary heart disease (CHD), its role in the pathogenesis of ischemic stroke is less clear. Epidemiological studies have provided conflicting findings regarding the association of dyslipidemia with ischemic stroke. Overall, elevated LDL-C levels appear to increase the risk of ischemic stroke. Low HDL-C levels also appear to be associated with a greater risk whereas the importance of high triglyceride levels is less clear. The discordant results of observational studies might result from the heterogeneity of stroke, since dyslipidemia is less likely to play a major role in the pathogenesis of some ischemic stroke subtypes (e.g. lacunar and cardioembolic strokes) and elevated LDL-C levels might increase the risk of hemorrhagic stroke. In clinical trials, statins consistently reduced the risk of ischemic stroke in patients with or without CHD whereas the data on the effects of other lipid modifying drugs on stroke risk are limited. In patients with a previous stroke, statins reduce the risk of both ischemic stroke and other vascular events but also increase the risk of hemorrhagic stroke. Accordingly, current guidelines recommend the same lipid targets for the primary and secondary prevention of both stroke and CHD. In addition, stroke and transient ischemic attacks of carotid origin are considered CHD risk equivalents. Nevertheless, more trials are required to identify which patients with stroke but without CHD will benefit more from statin treatment.
Keywords: ischemic stroke, hemorrhagic stroke, statins, fibrates, nicotinic acid, low density lipoprotein cholesterol, high density lipoprotein cholesterol, triglycerides
Current Topics in Medicinal Chemistry
Title: Dyslipidemia as a Risk Factor for Ischemic Stroke
Volume: 9 Issue: 14
Author(s): Konstantinos Tziomalos, Vasilios G. Athyros, Asterios Karagiannis and Dimitri P. Mikhailidis
Affiliation:
Keywords: ischemic stroke, hemorrhagic stroke, statins, fibrates, nicotinic acid, low density lipoprotein cholesterol, high density lipoprotein cholesterol, triglycerides
Abstract: Ischemic stroke is a major cause of morbidity and mortality. Whereas dyslipidemia is a major risk factor for coronary heart disease (CHD), its role in the pathogenesis of ischemic stroke is less clear. Epidemiological studies have provided conflicting findings regarding the association of dyslipidemia with ischemic stroke. Overall, elevated LDL-C levels appear to increase the risk of ischemic stroke. Low HDL-C levels also appear to be associated with a greater risk whereas the importance of high triglyceride levels is less clear. The discordant results of observational studies might result from the heterogeneity of stroke, since dyslipidemia is less likely to play a major role in the pathogenesis of some ischemic stroke subtypes (e.g. lacunar and cardioembolic strokes) and elevated LDL-C levels might increase the risk of hemorrhagic stroke. In clinical trials, statins consistently reduced the risk of ischemic stroke in patients with or without CHD whereas the data on the effects of other lipid modifying drugs on stroke risk are limited. In patients with a previous stroke, statins reduce the risk of both ischemic stroke and other vascular events but also increase the risk of hemorrhagic stroke. Accordingly, current guidelines recommend the same lipid targets for the primary and secondary prevention of both stroke and CHD. In addition, stroke and transient ischemic attacks of carotid origin are considered CHD risk equivalents. Nevertheless, more trials are required to identify which patients with stroke but without CHD will benefit more from statin treatment.
Export Options
About this article
Cite this article as:
Tziomalos Konstantinos, Athyros G. Vasilios, Karagiannis Asterios and Mikhailidis P. Dimitri, Dyslipidemia as a Risk Factor for Ischemic Stroke, Current Topics in Medicinal Chemistry 2009; 9 (14) . https://dx.doi.org/10.2174/156802609789869628
DOI https://dx.doi.org/10.2174/156802609789869628 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Artificial intelligence for Natural Products Discovery and Development
Our approach involves using computational methods to predict the potential therapeutic benefits of natural products by considering factors such as drug structure, targets, and interactions. We also employ multitarget analysis to understand the role of drug targets in disease pathways. We advocate for the use of artificial intelligence in predicting ...read more
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Multiple Roles of Fibroblast Growth Factor 21 in Metabolism
Current Pharmaceutical Design Editorial [Hot topic:Current Hypertension Reviews, Hot Topics “Obesity, Hypertension, and the Metabolic Syndrome” (Guest Editor: Kazuko Masuo)]
Current Hypertension Reviews Review of Endocrine Manifestations of Antiphospholid Syndrome
Current Rheumatology Reviews Historical Aspects and Relevance of the Human Coronary Collateral Circulation
Current Cardiology Reviews All for Statins and Statins for All; An Update
Current Pharmaceutical Design Muscarinic Acetylcholine Receptor-Interacting Proteins (mAChRIPs): Targeting the Receptorsome
Current Drug Targets Algorithms and Criteria for Transcatheter Aortic Valve Replacement Patient Selection: Current Status and Future Trends
Current Pharmaceutical Design Editorial (Thematic Issue: Aging and Metabolic Syndrome: Common Molecular Pathways)
Current Diabetes Reviews Treatment of Psoriasis: A Comprehensive Review of Entire Therapies
Current Drug Safety Implications of Epigenetic Mechanisms and their Targets in Cerebral Ischemia Models
Current Neuropharmacology Ultrasound Features of Polycystic Ovaries and Syndrome X: A Pilot Study
Vascular Disease Prevention (Discontinued) Clopidogrel Generic Formulations in the Era of New Antiplatelets: A Systematic Review
Current Vascular Pharmacology The Polymorphism at the microRNA-155 Binding Site in the AGTR1 Gene is not Significantly Associated with Rheumatic Heart Disease in Saudi Arabia Population
MicroRNA Nanoparticulated Quercetin in Combating Age Related Cerebral Oxidative Injury
Current Aging Science Metabolomics Analysis for Biomarker Discovery: Advances and Challenges
Current Medicinal Chemistry Whole Cell Biocatalysts for the Preparation of Nucleosides and their Derivatives
Current Pharmaceutical Design Neurohormonal Activation in Ischemic Stroke: Effects of Acute Phase Disturbances on Long-Term Mortality
Current Neurovascular Research Status of Cytokines in Ischemia Reperfusion Induced Heart Injury
Cardiovascular & Hematological Disorders-Drug Targets Lipases in Medicine: An Overview
Mini-Reviews in Medicinal Chemistry Obesity and Inflammation and Altered Clopidogrel Pharmacokinetics and Pharmacodynamics
Drug Metabolism Letters